

Message

From: Chou, Selene (ATSDR/DTEM/PRMSB) [cjc3@cdc.gov]
Sent: 7/21/2011 6:47:19 PM
To: Williams, Malcolm (ATSDR/DTEM/ATB) [mxw7@cdc.gov]; Faroon, Obaid (ATSDR/DTEM/ATB) [oxs0@cdc.gov]; Wilbur, Sharon (ATSDR/DTEM/ATB) [sdw9@cdc.gov]; Ashizawa, Annette (ATSDR/DTEM/ATB) [ada8@cdc.gov]; Demchuk, Eugene (ATSDR/DTEM/OD) [eed5@cdc.gov]; lxw2@cdc.gov [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1ab348928427450a949b82b978aa0c0e-lxw2@cdc.gov]; Sowell, Anne (ATSDR/DHS/OD) [als1@cdc.gov]; mkj5@cdc.gov [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=55e00d750b1a4701885d111c22ea4144-mkj5@cdc.gov]; Benson, Bob [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ccd3c8d2700447d2a9cc695b9a73340a-Benson, Bob]; 'Chhabrar@niehs.nih.gov' [Chhabrar@niehs.nih.gov]; Sofge, Christine (CDC/NIOSH/EID) [cts6@cdc.gov]; Wang, Richard (CDC/ONDIEH/NCEH) [rvw6@cdc.gov]; Jones, Samantha [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eac77fe3b20c4667b8c534c90c15a830-Jones, Samantha]; Edge, Charles (ATSDR/DTEM/PRMSB) [ibd7@cdc.gov]
CC: Murray, Ed (ATSDR/DTEM/OD) [hem0@cdc.gov]; Holler, James S. (Jim) (ATSDR/DTEM/PRMSB) [jsh2@cdc.gov]; jzw1@cdc.gov [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=09b8ce6b6a464b82a40dc7b4b33310d7-jzw1@cdc.gov]; Cvs1@cdc.gov [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=675aa9cfd6a4a32a46275693c3c0fdb-Cvs1@cdc.gov]; Abadin, Henry (ATSDR/DTEM/ATB) [hga0@cdc.gov]; Ingeman, Lisa [ingerman@srcinc.com]; Chou, Selene (ATSDR/DTEM/PRMSB) [cjc3@cdc.gov]
Subject: ATSDR MRL Workgroup Review of RDX
Attachments: BACKGROUND Sweeney et al 2010.pdf; BACKGROUND T3-1.pdf; BACKGROUND T3-2.pdf; MRL Worksheets_RDX.docx; RDX MRL rationale statement PPC dr2.docx; RDX_section 2.3.docx; BACKGROUND F3-1.pdf; BACKGROUND RDX Tox Profile.doc

Greetings everyone,

The RDX (Update) draft for public comment was released in November, 2010, in which an acute oral MRL and an intermediate oral MRL were derived. In the post public comment draft toxicological profile for RDX currently being finalized, the acute and intermediate oral MRLs for RDX are revised, in addition, a chronic oral MRL is derived (see email below from Henry Abadin, the RDX lead Chemical Manager). Please review the attached supporting documents and let me know your comments and/or your votes on these proposed MRLs by August 3rd, 2011.

Due to a tight deadline and that workgroup members are taking leave during summer, we are doing a paper review to allow for maximal participation.

Looking forward to hearing from you,

Selene

Selene Chou, Ph.D.
Chair, ATSDR MRL Workgroup
ATSDR/DTEM/PRMSB MS F62
1600 Clifton Road., N.E.
Atlanta, GA 30333
Tel: (770)48803357
Email: cjc3@cdc.gov

From: Abadin, Henry (ATSDR/DTEM/ATB)
Sent: Thursday, July 21, 2011 12:48 PM
To: Chou, Selene (ATSDR/DTEM/PRMSB)
Subject: RDX

A PBPK model became available and was utilized to recalculate the previously derived acute and intermediate duration MRLs. The key study (Army 2006) did not change.

U.S. Army (1983a) was used to derive a chronic-duration MRL; also utilizing the PBPK model.

The two Army studies will follow in separate emails.

Previous MRLs

Acute-duration oral - 0.09 mg/kg/day (U.S. Army, 2006)

Revised to: 0.2 mg/kg/day (U.S. Army, 2006) with application of PBPK model (Sweeney et al 2010).

Intermediate-duration oral - 0.05 mg/kg/day (U.S. Army, 2006)

Revised to: 0.1 mg/kg/day (U.S. Army, 2006) with application of PBPK model (Sweeney et al 2010).

New MRL

Chronic-duration oral - 0.1 mg/kg/day (U.S. Army, 1983a)